Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis (MIRSLA)
Etude de l'Expression Des Micro-RNA Comme Biomarqueur Diagnostic et Pronostic Dans la Sclérose Latérale Amyotrophique
Sponsor: University Hospital, Bordeaux
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from University Hospital, Bordeaux
Listed as NCT01992029, this observational or N/A phase trial focuses on ALS and Amyotrophic Lateral Sclerosis and remains terminated or withdrawn. Sponsored by University Hospital, Bordeaux, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 6 earlier versions
-
Dec 2018 — Nov 2020 [monthly]
Terminated
Status: Unknown Status → Terminated
-
Jun 2018 — Dec 2018 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Bordeaux
For direct contact, visit the study record on ClinicalTrials.gov .